Embla Medical hf Valuation
Is EMBLA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EMBLA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EMBLA (DKK30.9) is trading below our estimate of fair value (DKK36.51)
Significantly Below Fair Value: EMBLA is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EMBLA?
Other financial metrics that can be useful for relative valuation.
| What is EMBLA's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$1.89b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.9x |
| Enterprise Value/EBITDA | 20.5x |
| PEG Ratio | 1.8x |
Price to Earnings Ratio vs Peers
How does EMBLA's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 63.2x | ||
AMBU B Ambu | 98.4x | 25.7% | DKK 36.8b |
DEMANT Demant | 21.5x | 12.0% | DKK 55.7b |
NUVA NuVasive | 73.3x | 46.2% | US$2.1b |
LMAT LeMaitre Vascular | 59.7x | 13.0% | US$2.0b |
EMBLA Embla Medical hf | 31.4x | 17.9% | DKK 13.0b |
Price-To-Earnings vs Peers: EMBLA is good value based on its Price-To-Earnings Ratio (31.4x) compared to the peer average (59.3x).
Price to Earnings Ratio vs Industry
How does EMBLA's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: EMBLA is expensive based on its Price-To-Earnings Ratio (31.4x) compared to the European Medical Equipment industry average (30.4x).
Price to Earnings Ratio vs Fair Ratio
What is EMBLA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 31.4x |
| Fair PE Ratio | 36.8x |
Price-To-Earnings vs Fair Ratio: EMBLA is good value based on its Price-To-Earnings Ratio (31.4x) compared to the estimated Fair Price-To-Earnings Ratio (36.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | DKK 30.90 | DKK 35.06 +13.5% | 6.5% | DKK 39.00 | DKK 33.00 | n/a | 5 |
| Jul ’25 | DKK 29.60 | DKK 34.72 +17.3% | 7.2% | DKK 39.00 | DKK 32.00 | n/a | 5 |
| Jun ’25 | DKK 28.30 | DKK 34.52 +22.0% | 8.0% | DKK 39.00 | DKK 31.00 | n/a | 5 |
| May ’25 | DKK 29.90 | DKK 34.52 +15.5% | 8.0% | DKK 39.00 | DKK 31.00 | n/a | 5 |
| Apr ’25 | DKK 33.50 | DKK 34.16 +2.0% | 8.2% | DKK 39.00 | DKK 31.00 | n/a | 5 |
| Mar ’25 | DKK 31.70 | DKK 34.16 +7.8% | 8.2% | DKK 39.00 | DKK 31.00 | n/a | 5 |
| Feb ’25 | DKK 30.00 | DKK 33.96 +13.2% | 8.5% | DKK 39.00 | DKK 31.00 | n/a | 5 |
| Jan ’25 | DKK 27.45 | DKK 34.00 +23.9% | 8.3% | DKK 39.00 | DKK 31.00 | n/a | 5 |
| Dec ’24 | DKK 28.60 | DKK 34.00 +18.9% | 8.3% | DKK 39.00 | DKK 31.00 | n/a | 5 |
| Nov ’24 | DKK 25.80 | DKK 34.14 +32.3% | 8.0% | DKK 39.00 | DKK 31.00 | n/a | 5 |
| Oct ’24 | DKK 28.50 | DKK 37.10 +30.2% | 6.3% | DKK 39.00 | DKK 32.70 | n/a | 5 |
| Sep ’24 | DKK 30.10 | DKK 37.10 +23.3% | 6.3% | DKK 39.00 | DKK 32.70 | n/a | 5 |
| Aug ’24 | DKK 31.50 | DKK 37.10 +17.8% | 6.3% | DKK 39.00 | DKK 32.70 | n/a | 5 |
| Jul ’24 | DKK 32.15 | DKK 37.10 +15.4% | 6.3% | DKK 39.00 | DKK 32.70 | DKK 29.60 | 5 |
| Jun ’24 | DKK 31.00 | DKK 36.93 +19.1% | 7.0% | DKK 39.00 | DKK 32.70 | DKK 28.30 | 4 |
| May ’24 | DKK 32.15 | DKK 37.25 +15.9% | 5.5% | DKK 39.00 | DKK 34.00 | DKK 29.90 | 4 |
| Apr ’24 | DKK 31.00 | DKK 37.25 +20.2% | 5.5% | DKK 39.00 | DKK 34.00 | DKK 33.50 | 4 |
| Mar ’24 | DKK 33.60 | DKK 37.50 +11.6% | 5.5% | DKK 39.00 | DKK 34.00 | DKK 31.70 | 4 |
| Feb ’24 | DKK 32.50 | DKK 37.75 +16.2% | 4.3% | DKK 39.00 | DKK 35.00 | DKK 30.00 | 4 |
| Jan ’24 | DKK 33.55 | DKK 36.45 +8.6% | 5.1% | DKK 39.00 | DKK 33.80 | DKK 27.45 | 4 |
| Dec ’23 | DKK 32.60 | DKK 36.45 +11.8% | 5.1% | DKK 39.00 | DKK 33.80 | DKK 28.60 | 4 |
| Nov ’23 | DKK 34.10 | DKK 36.45 +6.9% | 5.1% | DKK 39.00 | DKK 33.80 | DKK 25.80 | 4 |
| Oct ’23 | DKK 29.80 | DKK 38.13 +27.9% | 7.7% | DKK 41.00 | DKK 34.50 | DKK 28.50 | 4 |
| Sep ’23 | DKK 26.90 | DKK 38.13 +41.7% | 7.7% | DKK 41.00 | DKK 34.50 | DKK 30.10 | 4 |
| Aug ’23 | DKK 30.05 | DKK 38.50 +28.1% | 6.5% | DKK 41.00 | DKK 36.00 | DKK 31.50 | 4 |
| Jul ’23 | DKK 30.00 | DKK 45.45 +51.5% | 4.1% | DKK 48.00 | DKK 42.80 | DKK 32.15 | 4 |
Analyst Forecast: Target price is less than 20% higher than the current share price.